Global biopharmaceutical company: An impossible timeline, delivered

1 min read

A biopharmaceutical company set out to file a lifesaving drug for approval in a timeframe its own team thought impossible. By turning that deadline into a public promise and building the ownership to keep it, the submission was delivered on time, bringing a new standard of care to patients across 43 countries.

Outcome 1: The drug submission was delivered within the committed 106 days
Outcome 2: Regulatory approval secured in Europe and, subsequently, the United States
Outcome 3: A new standard-of-care treatment reached patients, tested in an 18,624-patient study across 43 countries

The challenge

A major biopharmaceutical company set an ambitious goal: to submit a lifesaving drug for regulatory approval within 60 days, a timeframe the team itself believed was unrealistic. The project was slowed by a culture of unspoken resistance, unclear roles, and a body of data running to more than a million pages. Without a clear owner and a credible commitment, the submission would keep drifting.

Continued delay would waste the huge investment in the clinical trial and hold back patient access to a treatment already shown to be superior in an international study of 18,624 patients across 43 countries.

The approach

Working with the project leadership, we surfaced and dismantled the assumptions about what was possible. A revised 106-day timeline was set, not as a target but as a public promise. Alongside the team we designed clear lines of accountability, regular milestone reviews, and a shared sense of purpose centred on patients that replaced the previous passive culture.

The impact

The submission was delivered within the 106-day promise, and approval followed in Europe and then the United States. Patients gained access to a new standard-of-care treatment for a serious heart condition. As one team member put it, the achievement changed the people who worked on it as much as it changed the timeline.